Raymond James & Associates’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $86.2M | Buy |
|
|||||
|
2024
Q2 | $78M | Buy |
|
|||||
|
2024
Q1 | $68.7M | Buy |
|
|||||
|
2023
Q4 | $58.8M | Buy |
|
|||||
|
2023
Q3 | $50.6M | Sell |
|
|||||
|
2023
Q2 | $44.2M | Sell |
|
|||||
|
2023
Q1 | $51M | Buy |
|
|||||
|
2022
Q4 | $44.2M | Sell |
|
|||||
|
2022
Q3 | $45.9M | Sell |
|
|||||
|
2022
Q2 | $40M | Sell |
|
|||||
|
2022
Q1 | $62.6M | Sell |
|
|||||
|
2021
Q4 | $58.1M | Sell |
|
|||||
|
2021
Q3 | $58.3M | Sell |
|
|||||
|
2021
Q2 | $56.5M | Buy |
|
|||||
|
2021
Q1 | $43.1M | Sell |
|
|||||
|
2020
Q4 | $45.7M | Buy |
|
|||||
|
2020
Q3 | $52.6M | Sell |
|
|||||
|
2020
Q2 | $60.3M | Buy |
|
|||||
|
2020
Q1 | $41M | Buy |
|
|||||
|
2019
Q4 | $26.9M | Buy |
|
|||||
|
2019
Q3 | $19M | Buy |
|
|||||
|
2019
Q2 | $17.8M | Buy |
|
|||||
|
2019
Q1 | $22.1M | Sell |
|
|||||
|
2018
Q4 | $26.8M | Sell |
|
|||||
|
2018
Q3 | $33.2M | Buy |
|
|||||
|
2018
Q2 | $28.3M | Buy |
|
|||||
|
2018
Q1 | $17.9M | Buy |
|
|||||
|
2017
Q4 | $15.6M | Sell |
|
|||||
|
2017
Q3 | $19.9M | Buy |
|
|||||
|
2017
Q2 | $20.8M | Buy |
|
|||||
|
2017
Q1 | $15M | Buy |
|
|||||
|
2016
Q4 | $11.6M | Buy |
|
|||||
|
2016
Q3 | $10.1M | Buy |
|
|||||
|
2016
Q2 | $5.46M | Buy |
|
|||||
|
2016
Q1 | $5.12M | Sell |
|
|||||
|
2015
Q4 | $10.3M | Buy |
|
|||||
|
2015
Q3 | $6.47M | Sell |
|
|||||
|
2015
Q2 | $7.73M | Buy |
|